Research & Markets: One of UCB's biggest-selling Products, Keppra, Achieved Sales Growth of 34%.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47159) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: UCB UCB - University of California at Berkeley Prospects to 2010 to their offering. UCB is a global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency , allergy/respiratory diseases, immune and inflammatory disorders and oncology. Headquartered in Brussels, Belgium, it has over 8,500 employees worldwide. The Group has production and packaging facilities in Belgium, Switzerland, the US, Japan, Germany, India, Italy, Spain and South Korea (to be closed) and sells in more than 40 countries on all continents. During 2005, the Group disposed of the Surface Specialties business segment and transformed itself into a pure biopharmaceutical company. On 25th September 2006, UCB confirmed its intention to make a friendly cash and share offer for all the issued and to be issued shares in Schwarz Pharma. The companies Boards have agreed the terms of an offer, which Schwarz Pharmas Supervisory and Executive Boards unanimously intend to recommend. The enlarged company would be called UCB and continue to be based at UCBs current headquarters in Brussels, Belgium. It is anticipated that the combination of UCB and Schwarz Pharma would build the next-generation biopharmaceutical leader, with strong combined US and EU commercial power and pro-forma 2005 revenues of EUR EUR In currencies, this is the abbreviation for the Euro. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 3.3 billion. Current Growth Drivers One of UCBs biggest-selling products, Keppra, achieved sales growth of 34 per cent in 2005, to reach revenues of EUR 560 million. UCB is working to enhance the life cycle for Keppra. To this end, line extensions have been filed for its use in primary generalised myoclonic myoclonic pertaining to myoclonus. myoclonic epilepsy see glycoproteinosis. myoclonic jerk a generalized seizure consisting of a jerk of most muscles in the body. seizures, and as an intravenous solution formulation as a monotherapy for primary generalised seizures. Phase III trials are also under way in Japan for generalised tonic-clonic seizures and are planned for epilepsy in children aged one month to six years. Keppra is also in Phase II trials for other indications such as migraine or bipolar disorders are in the phase of exploratory clinical studies. Key Late-Stage Products Following Cimzias excellent Phase III results in Crohns disease, a BLA BLA abbr. Bachelor of Liberal Arts was submitted to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. on 1st March 2006 and an MAA MAA abbr. macroaggregated albumin to the EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. in April 2006. Approval is expected in the first half of 2007 and launch is targeted to follow shortly afterwards. It is also undergoing Phase III trials for rheumatoid arthritis (RA) and Phase II trials for psoriasis. UCB has licensed exclusive worldwide rights to develop, market and sell epratuzumab for all autoimmune disease indications, from Immunomedics. The most advanced programme is for the treatment of systemic lupus erythematosus Systemic Lupus Erythematosus Definition Systemic lupus erythematosus (also called lupus or SLE) is a disease where a person's immune system attacks and injures the body's own organs and tissues. Almost every system of the body can be affected by SLE. (SLE SLE systemic lupus erythematosus. SLE abbr. systemic lupus erythematosus Systemic lupus erythematosus (SLE) ), for which it has been granted FDA fast track Fast Track is a designation of the Food and Drug Administration that accelerates the approval of experimental drugs, such as experimental cancer treatments, that treat a serious or life-threatening medical condition for which no other drug either exists or works as well. designation. UCB voluntarily suspended dosing in the Phase III SLE trials in mid-2006, however, following a routine quality assurance audit of Immunomedics facilities. The FDA placed epratuzumab on clinical hold, while Immunomedic and UCB address its concerns, so that patients who have already benefited from epratuzumab are able to resume treatment as soon as possible. Products Mentioned Include: ATI-7505 Topics Covered Principal Operating Results Breaking News Latest Results Introduction Current Growth Drivers Key Late-Stage Products Key Early-Stage Products Financial Performance 2005 Sales and Market Position Income Operating Profit By Business Segment Expenditure Capital Expenditure Investments By Business Area R&D Expenditure R&D Expenditure By Business Area Divisional Performance Consolidated Turnover By Business Area Geographic Performance Total Revenues By Geographic Area Net Biopharmaceutical Sales By Geographical Area Company Strategy Mergers, Acquisitions and Divestitures Acquisitions Divestitures Key Agreements Production Employees Employees By Geographical Area (Year End) Product / R&D Overview Key Products Recent Product Launches Recent Product Approvals R&D Strategy Key R&D Projects R&D Pipeline Overview Discontinued R&D projects Sales Forecasts Conclusions/Outlook PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT APPENDIX 1 FINANCIAL PERFORMANCE APPENDIX 2 KEY AGREEMENTS APPENDIX 3 INFRASTRUCTURE APPENDIX 4 KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES APPENDIX 5 PRODUCT INDEX Companies Mentioned - Actelion Ltd - Adams Respiratory Therapeutics - Amgen - AstraZeneca - Biogen Idec Inc - BioInvent International AB - Crucell NV - DSM 1. DSM - Data Structure Manager. An object-oriented language by J.E. Rumbaugh and M.E. Loomis of GE, similar to C++. It is used in implementation of CAD/CAE software. DSM is written in DSM and C and produces C as output. Biologics - ImClone Systems Inc - Immunomedics Inc - Lonza Biologics Ltd - Merck & Co - Nektar Therapeutics - Orphan Medical - Pfizer - Recordati - sanofi-aventis - Sepracor Inc - Verus Pharmaceuticals Inc - Watson Pharmaceuticals Inc For more information visit http://www.researchandmarkets.com/reports/c47159 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion